• Leading program for
    Alzheimer's disease in
    Phase 3 clinical trials.

    Read more

  • Neurimmune’s anti-alpha-
    synuclein antibody
    program for Parkinson in Phase 1.

    Read more

  • RTM™ Technology Platform:
    Creating an entirely novel
    generation of drugs with
    excellent safety and efficacy
    profiles by reverse
    translational medicine.

    Read more


Neurimmune is a biopharmaceutical company dedicated to the development of innovative immunotherapeutics for human diseases. Its Reverse Translational Medicine™ platform generates recombinant human monoclonal antibodies with unique therapeutic properties. Together with target selectivity and high affinities these antibodies combine superior risk profiles with excellent efficacy.

Neurimmune has partnered four antibody programs with Biogen Idec. Antibody Aducanumab (BIIB037) for Alzheimer's disease is currently in Phase 3 clinical trials. The therapeutic antibody for Parkinson’s disease (BIIB054) is in Phase 1. Therapeutic antibodies for tauopathies and fronto-temporal dementia are in preclinical stages.

Neurimmune’s program packages for amyotrophic lateral sclerosis, transthyretin amyloidosis and type-2 diabetes are validated with preclinical proof-of-concept. They are ready for partnering